Enfortumab vedotin

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Carcinoma, Transitional Cell

Conditions

Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms

Trial Timeline

Oct 8, 2017 → Jul 28, 2023

NCT ID

NCT03219333

About Enfortumab vedotin

Enfortumab vedotin is a phase 2 stage product being developed by Astellas Pharma for Carcinoma, Transitional Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT03219333. Target conditions include Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07139977	Phase 2	Recruiting	Apr 1, 2026	May 31, 2028	Endometrial Cancer
NCT07347314	Phase 2	Recruiting	Nov 4, 2025	Sep 30, 2028	Advanced Small Bowel Adenocarcinoma
NCT06862219	Approved	Recruiting	Jun 21, 2025	Dec 31, 2027	Metastatic Urothelial Carcinoma
NCT06891560	Phase 2	Recruiting	Mar 31, 2025	Mar 1, 2027	Adenoid Cystic Carcinoma
NCT06553885	Phase 2	Recruiting	Mar 24, 2025	Sep 1, 2029	Metastatic Colorectal Cancer
NCT06394570	Phase 1/2	Recruiting	Sep 10, 2024	Jul 1, 2027	Bladder Cancer
NCT06011954	Pre-clinical	Recruiting	Nov 1, 2023	Jul 31, 2027	Urothelial Cancer
NCT05868265	Phase 2	Recruiting	Jun 2, 2023	Jun 2, 2027	Urothelial Carcinoma
NCT04754191	Phase 2	Active	Jun 5, 2022	Jan 1, 2027	Metastatic Castration-resistant Prostate Cancer
NCT05014139	Phase 1	Terminated	Dec 7, 2021	Sep 22, 2025	Urinary Bladder Neoplasms
NCT04995419	Phase 2	Completed	Jul 22, 2021	Aug 27, 2025	Metastatic Urothelial Cancer
NCT03219333	Phase 2	Completed	Oct 8, 2017	Jul 28, 2023	Carcinoma, Transitional Cell
NCT03070990	Phase 1	Completed	Apr 24, 2017	Feb 25, 2019	Metastatic Urothelial Cancer
NCT02091999	Phase 1	Completed	May 14, 2014	Dec 7, 2022	Metastatic Urothelial Cancer and Other Malignant Solid Tumors

Competing Products

20 competing products in Carcinoma, Transitional Cell

See all competitors

Product	Company	Stage	Hype Score
AFM24 + SNK01	Affimed	Phase 1/2	33
NRC-2694-A + Paclitaxel	Natco Pharma	Phase 2	51
Sintilimab + Nab paclitaxel + Cisplatin	CSPC Pharmaceutical Group Limited	Phase 2	51
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	30
Pemetrexed + Carboplatin	Eli Lilly	Phase 3	77
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cells	Precigen	Phase 1	28
Cemiplimab + Cetuximab	Eli Lilly	Phase 2	52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU	Eli Lilly	Phase 2	52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359	Perspective Therapeutics	Phase 1/2	33
CT-01 + EVEROLIMUS	Captor Therapeutics	Phase 1	25
BB-401	Benitec Biopharma	Phase 2	44
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	44
Azenosertib	Zentalis Pharmaceuticals	Phase 2	44
6-Thio-2'-Deoxyguanosine + Cemiplimab	MAIA Biotechnology	Phase 2	44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone	MAIA Biotechnology	Phase 3	69
ateganosine + Cadonilimab	MAIA Biotechnology	Phase 1	25
gemcitabine + carboplatin + cisplatin	Eli Lilly	Phase 2	52
Cetuximab	Eli Lilly	Phase 1	33
Ramucirumab + Paclitaxel	Eli Lilly	Phase 2	52
LY2875358 + Erlotinib	Eli Lilly	Phase 2	52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved